Amylyx Pharmaceuticals (AMLX) Other Accumulated Expenses (2021 - 2022)
Amylyx Pharmaceuticals (AMLX) recorded quarterly Other Accumulated Expenses of $1.0 million in Q4 2022, up 182.3% quarter-over-quarter from $356000.0 in Q3 2022, and up 289.53% on a YoY basis from $258000.0 in Q4 2021.
Amylyx Pharmaceuticals (AMLX) Other Accumulated Expenses (2021 - 2022) Analysis & Trends
Amylyx Pharmaceuticals' Other Accumulated Expenses history runs 2 years deep, the most recent figure standing at $1.0 million for Q4 2022.
- In Q4 2022, Other Accumulated Expenses rose 289.53% year-over-year to $1.0 million; the TTM figure through Dec 2022 stood at $1.0 million (up 289.53% YoY), while the FY2022 annual figure was $1.0 million, up 289.53% from the prior year.
- Other Accumulated Expenses was $1.0 million for Q4 2022 at Amylyx Pharmaceuticals, up from $356000.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $1.0 million in Q4 2022 to a low of $258000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Amylyx Pharmaceuticals | 1.51 Bn | 1.51 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 1.01 Mn |
| Sep 30, 2022 | 356,000.00 |
| Jun 30, 2022 | 535,000.00 |
| Mar 31, 2022 | 439,000.00 |
| Dec 31, 2021 | 258,000.00 |